Therapeutic angiogenesis using genetically engineered human endothelial cells

Seung-Woo Cho, Fan Yang, Sun Mi Son, Hyun Ji Park, Jordan J. Green, Said Bogatyrev, Ying Mei, Sohyun Park, Robert Langer, Daniel G. Anderson

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Cell therapy holds promise as a method for the treatment of ischemic disease. However, one significant challenge to the efficacy of cell therapy is poor cell survival in vivo. Here we describe a non-viral, gene therapy approach to improve the survival and engraftment of cells transplanted into ischemic tissue. We have developed biodegradable poly(β-amino esters) (PBAE) nanoparticles as vehicles to genetically modify human umbilical vein endothelial cells (HUVECs) with vascular endothelial growth factor (VEGF). VEGF transfection using these nanoparticles significantly enhanced VEGF expression in HUVECs, compared with a commercially-available transfection reagent. Transfection resulted in the upregulation of survival factors, and improved viability under simulated ischemic conditions. In a mouse model of hindlimb ischemia, VEGF nanoparticle transfection promoted engraftment of HUVECs into mouse vasculature as well as survival of transplanted HUVECs in ischemic tissues, leading to improved angiogenesis and ischemic limb salvage. This study demonstrates that biodegradable polymer nanoparticles may provide a safe and effective method for genetic engineering of endothelial cells to enhance therapeutic angiogenesis.

Original languageEnglish
Pages (from-to)515-524
Number of pages10
JournalJournal of Controlled Release
Volume160
Issue number3
DOIs
Publication statusPublished - 2012 Jun 28

Fingerprint

Human Umbilical Vein Endothelial Cells
Nanoparticles
Vascular Endothelial Growth Factor A
Transfection
Endothelial Cells
Cell- and Tissue-Based Therapy
Cell Survival
Limb Salvage
Genetic Engineering
Survival
Therapeutics
Hindlimb
Genetic Therapy
Polymers
Esters
Up-Regulation
Ischemia

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Cho, S-W., Yang, F., Son, S. M., Park, H. J., Green, J. J., Bogatyrev, S., ... Anderson, D. G. (2012). Therapeutic angiogenesis using genetically engineered human endothelial cells. Journal of Controlled Release, 160(3), 515-524. https://doi.org/10.1016/j.jconrel.2012.03.006
Cho, Seung-Woo ; Yang, Fan ; Son, Sun Mi ; Park, Hyun Ji ; Green, Jordan J. ; Bogatyrev, Said ; Mei, Ying ; Park, Sohyun ; Langer, Robert ; Anderson, Daniel G. / Therapeutic angiogenesis using genetically engineered human endothelial cells. In: Journal of Controlled Release. 2012 ; Vol. 160, No. 3. pp. 515-524.
@article{b1f15875aec84cb0ac626c4c08f8d637,
title = "Therapeutic angiogenesis using genetically engineered human endothelial cells",
abstract = "Cell therapy holds promise as a method for the treatment of ischemic disease. However, one significant challenge to the efficacy of cell therapy is poor cell survival in vivo. Here we describe a non-viral, gene therapy approach to improve the survival and engraftment of cells transplanted into ischemic tissue. We have developed biodegradable poly(β-amino esters) (PBAE) nanoparticles as vehicles to genetically modify human umbilical vein endothelial cells (HUVECs) with vascular endothelial growth factor (VEGF). VEGF transfection using these nanoparticles significantly enhanced VEGF expression in HUVECs, compared with a commercially-available transfection reagent. Transfection resulted in the upregulation of survival factors, and improved viability under simulated ischemic conditions. In a mouse model of hindlimb ischemia, VEGF nanoparticle transfection promoted engraftment of HUVECs into mouse vasculature as well as survival of transplanted HUVECs in ischemic tissues, leading to improved angiogenesis and ischemic limb salvage. This study demonstrates that biodegradable polymer nanoparticles may provide a safe and effective method for genetic engineering of endothelial cells to enhance therapeutic angiogenesis.",
author = "Seung-Woo Cho and Fan Yang and Son, {Sun Mi} and Park, {Hyun Ji} and Green, {Jordan J.} and Said Bogatyrev and Ying Mei and Sohyun Park and Robert Langer and Anderson, {Daniel G.}",
year = "2012",
month = "6",
day = "28",
doi = "10.1016/j.jconrel.2012.03.006",
language = "English",
volume = "160",
pages = "515--524",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

Cho, S-W, Yang, F, Son, SM, Park, HJ, Green, JJ, Bogatyrev, S, Mei, Y, Park, S, Langer, R & Anderson, DG 2012, 'Therapeutic angiogenesis using genetically engineered human endothelial cells', Journal of Controlled Release, vol. 160, no. 3, pp. 515-524. https://doi.org/10.1016/j.jconrel.2012.03.006

Therapeutic angiogenesis using genetically engineered human endothelial cells. / Cho, Seung-Woo; Yang, Fan; Son, Sun Mi; Park, Hyun Ji; Green, Jordan J.; Bogatyrev, Said; Mei, Ying; Park, Sohyun; Langer, Robert; Anderson, Daniel G.

In: Journal of Controlled Release, Vol. 160, No. 3, 28.06.2012, p. 515-524.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Therapeutic angiogenesis using genetically engineered human endothelial cells

AU - Cho, Seung-Woo

AU - Yang, Fan

AU - Son, Sun Mi

AU - Park, Hyun Ji

AU - Green, Jordan J.

AU - Bogatyrev, Said

AU - Mei, Ying

AU - Park, Sohyun

AU - Langer, Robert

AU - Anderson, Daniel G.

PY - 2012/6/28

Y1 - 2012/6/28

N2 - Cell therapy holds promise as a method for the treatment of ischemic disease. However, one significant challenge to the efficacy of cell therapy is poor cell survival in vivo. Here we describe a non-viral, gene therapy approach to improve the survival and engraftment of cells transplanted into ischemic tissue. We have developed biodegradable poly(β-amino esters) (PBAE) nanoparticles as vehicles to genetically modify human umbilical vein endothelial cells (HUVECs) with vascular endothelial growth factor (VEGF). VEGF transfection using these nanoparticles significantly enhanced VEGF expression in HUVECs, compared with a commercially-available transfection reagent. Transfection resulted in the upregulation of survival factors, and improved viability under simulated ischemic conditions. In a mouse model of hindlimb ischemia, VEGF nanoparticle transfection promoted engraftment of HUVECs into mouse vasculature as well as survival of transplanted HUVECs in ischemic tissues, leading to improved angiogenesis and ischemic limb salvage. This study demonstrates that biodegradable polymer nanoparticles may provide a safe and effective method for genetic engineering of endothelial cells to enhance therapeutic angiogenesis.

AB - Cell therapy holds promise as a method for the treatment of ischemic disease. However, one significant challenge to the efficacy of cell therapy is poor cell survival in vivo. Here we describe a non-viral, gene therapy approach to improve the survival and engraftment of cells transplanted into ischemic tissue. We have developed biodegradable poly(β-amino esters) (PBAE) nanoparticles as vehicles to genetically modify human umbilical vein endothelial cells (HUVECs) with vascular endothelial growth factor (VEGF). VEGF transfection using these nanoparticles significantly enhanced VEGF expression in HUVECs, compared with a commercially-available transfection reagent. Transfection resulted in the upregulation of survival factors, and improved viability under simulated ischemic conditions. In a mouse model of hindlimb ischemia, VEGF nanoparticle transfection promoted engraftment of HUVECs into mouse vasculature as well as survival of transplanted HUVECs in ischemic tissues, leading to improved angiogenesis and ischemic limb salvage. This study demonstrates that biodegradable polymer nanoparticles may provide a safe and effective method for genetic engineering of endothelial cells to enhance therapeutic angiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84861979906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861979906&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2012.03.006

DO - 10.1016/j.jconrel.2012.03.006

M3 - Article

VL - 160

SP - 515

EP - 524

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -